Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2189668 | 1.00 | — | — | |
| SCHEMBL388479 | 0.97 | — | — | |
| Propane SCHEMBL8099786 | 0.90 | HTR2A (0.37) | — | |
| SCHEMBL23010220 | 0.83 | HTR2A (0.33) | — | |
| SCHEMBL21795199 | 0.79 | KISS1R (0.33) | — | |
| SCHEMBL18788229 | 0.79 | KISS1R (0.33) | — | |
| SCHEMBL23010168 | 0.79 | KISS1R (0.33) | — | |
| SCHEMBL19646488 | 0.79 | LMNA (0.39) | — | |
| SCHEMBL18551184 | 0.79 | KISS1R (0.33) | — | |
| SCHEMBL172994 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463445-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | DORPHAN S A (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250073198-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ß-GALACTOSIDASE ACTIVITY | DORPHAN S.A. (CH) | 2025-03-06 | — | — | US | disclosed |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| EP-4463445-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED ?-GALACTOSIDASE ACTIVITY | Dorphan S.A. (CH) | 2024-11-20 | — | — | EP | disclosed |
| EP-4452965-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-10-30 | — | — | EP | disclosed |
| CN-118541378-A | Novel auristatin analogues and immunoconjugates thereof | 艾德森特克斯治疗股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023135480-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IMPAIRED β-GALACTOSIDASE ACTIVITY | DORPHAN SA (CH) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023118253-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-06-29 | — | — | WO | disclosed |
| CN-116332873-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114025844-B | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-07-26 | — | — | CN | disclosed |
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299246-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020186199-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| US-7629346-B2 | Pyrazinecarboxamide derivatives as CB1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| EP-2035394-B1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-2035394-A1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
| WO-2007147746-A1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293509-A1 | Pyrazinecarboxamide derivatives as CB1 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-20 | — | — | US | disclosed |
| US-4658013-A | CONTAINING ALANINE, PHENYLALANINE AND/OR TYROSINE OR METHIONINE | STERLING DRUG INC. (US) | 1987-04-14 | — | — | US | disclosed |